IGF::OT::IGF OTHER FUNCTIONS - NOVEL IMAGING AGENTS TO EXPAND THE CLINICAL TOOLKIT FOR CANCER DIAGNOSIS, STAGING, AND TREATMENT

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N43CO120058
Agency Tracking Number: N43CO120058
Amount: $249,724.00
Phase: Phase I
Program: SBIR
Awards Year: 2012
Solicitation Year: 2012
Solicitation Topic Code: NCI
Solicitation Number: N/A
Small Business Information
34 FRANKLIN STREET, NASHUA, NH, 99999-
DUNS: 036787257
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 RON WEISS
 (603) 881-3322
 RON@ARKIVAL.COM
Business Contact
 RON WEISS
Phone: (603) 881-3322
Email: RON@ARKIVAL.COM
Research Institution
 Stub
Abstract
This technology introduces a new non-invasive, biopsy-adjunct with a MNP platform for targeted tumor delivery. It employs closely sized magnetic nanoparticles (CS-MNP's) for determining their concentration and spatial distribution in tumor vasculatures asmeasured by magnetic resonance imaging (MRI). The relationship between CS-MNP size and Vibrating Sample Magnetometer (VSM) measurement follows from the physics of superparamagnetism (SP- theory). By correlating particle size and concentration within a tumor and its MRI response, the data can likely deliver tumor characterization without biopsy. This work characterizes CS-MNP's, animal testing and the quantification of the MRI imaging signals. Resulting data supports continued development of CS-MNP-products and new patents. It addresses the production of CS- MNP products for preclinical studies and business development for a very large market requiring more precise, higher margin products. These new products and services represent the future of MNP-based products for imaging and drug delivery. This technology has potential for a new biopsy-adjunct with CS-MNP's for targeted tumor delivery. Measurement of CS-MNP's in the tumor vasculature by MRI may become a major diagnostic tool and use for targeted therapeutics. It may provide for differentiating benign disease from malignancy, insightful surgical planning, and evaluation of chemotherapy and radiation treatment

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government